

1 DRAFT
2
3
4
5
6
7
8
9

10 **ADVISORY COMMITTEE ON NOVEL FOODS AND**
11 **PROCESSES**
12
13

14 **DRAFT MINUTES OF THE EIGHTY THIRD MEETING**
15 **HELD ON 18 JULY 2007**
16
17
18
19
20
21

22 ACNFP Secretariat
23 Room 515B
24 Aviation House
25 125 Kingsway
26 London WC2B 6NH
27 Tel: (0)20 7276 8595
28 Fax: (0)20 7276 8564
29
30
31
32
33

34 ***These Minutes are subject to confirmation by the Committee at its next***
35 ***meeting.***

1 **DRAFT/ACNFP/83/MIN**

2

3

4 **DRAFT MINUTES OF THE EIGHTY THIRD MEETING OF THE ADVISORY**
5 **COMMITTEE ON NOVEL FOODS AND PROCESSES, HELD ON 18 MAY 2007 IN**
6 **CONFERENCE ROOM 5, AVIATION HOUSE.**

7

8

9 **Present** Professor Mike Gasson – **Chairman**
10 Ms Jill Brand
11 Dr Paul Brantom
12 Professor Ruth Chadwick
13 Mr Neville Craddock
14 Ms Jayam Dalal
15 Dr Peter Lund
16 Dr Clare Mills
17 Professor Peter Shewry
18 Professor John Warner

19

20

21 **Apologies** Professor Harry Flint
22 Professor Gary Foster
23 Professor Stephen Holgate
24 Professor Alan Malcolm
25 Dr Anthony Williams

26

27 **FSA Assessor** Dr Clair Baynton

28

29 **FSA Observers** Mr Graham Dunn (External Affairs Team)
30 Ms Sarah Hardy (Food Allergy Team)
31 Mr Noel Griffin (Nutrition Strategy Team, Item 8)

32

33 **Secretariat** Ms Alison Asquith
34 Ms Shuhana Begum
35 Dr Chris Jones
36 Dr Sandy Lawrie – **ACNFP Secretary** (Items 1-6, 8-11)
37 Dr Ana Miljkovic-Brake
38 Dr Trudy Netherwood (Items 1-5)
39 Ms Annie-Laure Robin
40 Ms Sandeep Virdee – **Minutes**

41

42

43

44

45 *Members are required to declare any personal interest in matters under discussion.*
46 *Where Members have a particularly close association with any item, the Chairman*
47 *will limit their involvement in the discussion. In cases where an item is to be*
48 *discussed in their absence, a Member may make a statement before leaving.*

1 provided but Members considered that it was not possible to extrapolate from
2 the available data to the situation in young children, whose gut flora is
3 developing and does not have an adult composition. It is known that children
4 are more sensitive than adults to the laxative effects of other poorly absorbed
5 ingredients e.g. polyols, and the Committee could not be certain that PDP will
6 be tolerated to the same extent by children as by adults. PDP was being
7 proposed for use in a wide range of different food types and, in the event that
8 it did result in GI symptoms such as diarrhoea in young children, it may be
9 difficult for parents or clinicians to make a link between consumption of the
10 ingredient and the onset of symptoms.

11 The Committee welcomed the new information provided by the applicant
12 concerning the glycemic response to PDP, but noted the theoretical possibility
13 that insulin-dependent diabetics might suffer hypoglycemia if their insulin dose
14 was calculated on the basis of the glucose content of a meal that included the
15 ingredient. Members also noted the applicant's revised proposal for naming
16 the ingredient, but questioned whether this was consistent with general food
17 labelling regulations that require an ingredient to be identified using its legal
18 name, where one has already been agreed.

19 **6. Astaxanthin rich oleoresin from Haematococcus ACNFP/83/4**
20 **pluvialis algae**

21 The Committee was asked to consider an opinion on the equivalence of the
22 applicant's astaxanthin-rich extract obtained from *H. pluvialis* algae using
23 supercritical carbon dioxide extraction technology compared with an existing
24 Astaxanthin-rich extract from the same source.

25 Overall the Committee had no objections on this application but pointed out
26 that any additives, such as antioxidants, that are used in the formulation of the
27 product should comply with EU legislation. The Secretariat agreed to prepare
28 a formal draft opinion for consideration by the Committee at the next meeting.

29 **7. Kiwiberry Concentrate ACNFP/83/5**

30 The Committee was asked to consider this new full application for a water
31 extracted concentrate of dried hardy kiwi fruit (*Actinidia arguta*). Hardy kiwi is
32 in the same genus as the familiar green kiwi (*Actinidia deliciosa*), but is
33 smaller with a fuzzless skin. The applicant proposed to market their kiwiberry
34 concentrate, including a powdered form, for incorporation into a range of food
35 products such as beverages, cereals and cereal products, milk and milk
36 products, sugars, preserves and confectionary, and savoury snacks.

37 The Committee agreed that, based on the information provided by the
38 applicant, there were no toxicity or nutritional concerns over this novel
39 ingredient. Members highlighted the key issue to be allergenicity, given that
40 allergy to green kiwi fruit is of increasing concern in the UK and across
41 Europe.

1 In this regard the Committee noted that the applicant had provided data from
2 a study which indicated that a small proportion of people with allergy to green
3 kiwi may also react to the novel ingredient. This was a small study on only 12
4 subjects and it was not possible to make a confident estimate of the true
5 incidence of cross-reactivity. On the basis that people with existing kiwi
6 allergy would be advised to avoid the novel ingredient, the Committee was
7 concerned that it was being proposed for use in a very broad range of food
8 categories, and that this could result in a significant reduction in the foods that
9 could safely be consumed by people with kiwi allergy. As many of these
10 foods would not currently be expected to contain kiwi products, there was a
11 significant risk that allergic individuals would not check the ingredient lists and
12 would suffer reactions as a result of accidental consumption of the kiwiberry
13 concentrate.

14 The Members therefore requested further information from the applicant on
15 the likely product range, the current sales of the novel ingredient and hardy
16 kiwi fruit outside the EU, and what steps the company were taking to ensure
17 that the product was not consumed by individuals with existing kiwi allergy.

18 The Secretariat agreed to seek further information from the applicant on these
19 points.

20 **8. Nutrition and Health Claims** **ACNFP/83/6**

21 The Committee had previously asked about controls on nutrition and health
22 claims that might be made for novel foods and novel ingredients, as the
23 assessment of such claims is not part of the evaluation and authorisation
24 procedures set out in the novel foods regulation (EC regulation 258/97).

25 Mr Noel Griffin from the Agency's Fortification and Claims Unit gave an
26 overview of the legislation governing nutrition and health claims, which applies
27 to all foods including novel foods. The EC Regulation on nutrition and health
28 claims came into force on 19 January and applies from 1 July 2007. The
29 Agency recently completed a consultation on the enforcement measures that
30 would implement this Regulation in the UK, together with guidelines to
31 compliance and a regulatory impact assessment. The Agency expected that
32 the enforcement measures would be in place in the autumn and would publish
33 its final guidance to compliance as soon as possible.

34 The Agency was also assembling a national list of generally accepted claims
35 to be submitted for consideration by EFSA (the European Food Safety
36 Authority). A list of EU approved claims was expected to be in place by
37 [date]. Until that time, claims would remain subject to general food labelling
38 legislation that prohibits claims that are untrue or otherwise misleading to the
39 consumer.

40 The Committee noted the presentation.

1 **9. Open Meetings** **(oral update)**

2 This was discussed in the May meeting where the Committee agreed to hold
3 an open meeting on general topics of interest to the public. The Secretariat is
4 finalising details of the meeting to be held in November and will circulate
5 further information when the venue is confirmed.

6 **10. Items for Information**

7 10.1 EU Update **ACNFP/83/8**

8 10.2 EFSA Statement on MON863 Maize **ACNFP/83/9**
9 **and Addendum**

10 The Secretariat tabled an addendum to ACNFP/83/9, containing a document
11 produced in response to EFSA's statement by the organisation CRIIGEN.
12 The Committee noted these papers without comment.

13 **11. Any Other Business**

14 The Secretariat informed the Committee that an advertisement for new
15 members to the ACNFP would appear in *The Guardian* and *Nature* the
16 following week.

17 The Committee were asked by the Secretariat to confirm their availability for
18 the ACNFP meetings to be held next year.

19 Jayam Dalal had attended a Consumer Representative training event,
20 organised jointly by the FSA and Foodaware, on 21 June and agreed to
21 forward papers from the event to the Secretariat for circulation to other
22 members.

23 **12. Date of next meeting**

24 The next meeting was scheduled for Thursday 20 September in Aviation
25 House.